Vijaya Diagnostic Centre Limited (VIJAYA) Fair Value & Analysis
Healthcare · IN · Market cap ₹140B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +6.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹861.40 – ₹1,398 · fair‑value band ₹217.15 – ₹566.91 · the ₹1,365 price screens above the ₹367.74 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Vijaya Diagnostic Centre Limited (VIJAYA) currently trades at ₹1,365, while our model-based Fair Value estimate is ₹367.74 — implying the stock looks roughly 73.1% overvalued today. We read business quality at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Vijaya Diagnostic Centre Limited generated revenue of ₹8.1B at a net margin of 21.3%. Revenue grew 26.6% year over year. It earns a return on equity of 19.7%. Net debt stands at ₹3.8B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, molecular diagnostics, CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, gastroenterology, nuclear medicine and PET/CT, and MRI-3T services. It also provides health checkups and home sample collection services. Vijaya Diagnostic Centre Limited was founded in 1981 and is based in Hyderabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Vijaya Diagnostic Centre Limited reported revenue of ₹8.1B in FY2026 versus ₹4.6B in FY2022, a compound +15.2%/yr. Reported net income was ₹1.7B in FY2026, compounding +12.1%/yr from FY2022.
Is VIJAYA fairly valued? → Check now
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $464.01 | $326.81 | -30% |
| Danaher Corporation DHR | $178.19 | $112.34 | -37% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $556.94 | $255.77 | -54% |
| Lonza Group LZAGY | $63.74 | $25.98 | -59% |
| Agilent Technologies, Inc A | $126.49 | $63.09 | -50% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Vijaya Diagnostic Centre Limited (VIJAYA) undervalued?
What is the fair value of VIJAYA?
What is the quality score of VIJAYA?
What is the revenue of Vijaya Diagnostic Centre Limited (VIJAYA)?
What is the net profit margin of VIJAYA?
Does Vijaya Diagnostic Centre Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.